ACC Expert Consensus on Same-Day Discharge post-PCI

Expecting expensive institutions to become more cost efficient is not a viable avenue for making health care affordable and available.

Affordability and accessibility come instead from disruptive innovations that enable less expensive venues of care to become capable of doing progressively more sophisticated things, with equal or better quality than their high-cost counterparts. ”

– Clayton M. Christensen, The Innovator’s Prescription: A Disruptive Solution for Health Care

To change the costs and availability of healthcare, we have to inquire if all of the assumptions and components of “standard of care” are there due to clinical necessity or simply because they have always been there. The 2021 ACC Expert Consensus Decision Pathway on Same-Day Discharge (SDD) after PCI1 compels us to take a hard look at the way we approach percutaneous coronary interventions (PCI) and potentially to expand elective PCI to more diverse sites of service.

Led by Dr. Sunil Rao, the working group addresses the many reasons that we should be carefully considering SDD for many patients undergoing elective PCI (excluding those presenting with ST segment elevation myocardial infarction (STEMI) or non-ST segment elevation myocardial infarction (NSTEMI)).

To help launch this paradigm of SDD into practice, the authors provide approachable and adaptable checklists to ensure each individual case is carefully assessed in terms of the appropriateness of SDD.

Stepping back, this ACC document reminds us of the procedural maturity of modern PCI, both in terms of consistent safety as well as the need to continue to advance further than we are now. This contextual shift toward SDD will now enable innovative providers to push toward office- or ASC-based outpatient PCI, bringing the same convenience, safety, and accessibility to this important piece of modern heartcare that patients enjoy with other outpatient procedures. For example, the safety of orthopedics means there’s no reason to be in the hospital for an ACL repair or elective hip replacement, and now PCI can move into that same space.

As PCI becomes more outpatient focused, interventional teams must ensure that they know precisely what they will encounter in each PCI before the patient is on the table. How long is this procedure likely to take? What tools will we need? Is there a chronic total occlusion (CTO)? Is LM disease present? Are there bifurcation lesions? Which vessels are diseased and which have physiologic evidence indicating they should be treated? What C-arm angulations allow for optimal visualization of each lesion? Where is there bulky plaque, and where is there coronary calcium?

In today’s world, the diverse answers to these questions highlight the case-to-case variation clinicians experience in the cath lab. But a shift toward highly repeatable, highly predictable PCI highlights how crucial it is to have line of sight to these variations pre-procedurally, which is best provided by evaluating patients with a coronary CTA+HeartFlow FFRCT pathway. CTA+HeartFlow is uniquely able to answer these vital questions and allow clinicians to anticipate the complexities of each PCI and plan for them in an effective way to help improve the probability of success. The CTA+HeartFlow pathway gives insights that enable cath lab teams to move beyond diagnostics, advancing to intervention fully informed.

The ACC indicates that “the success of the solution sets rests firmly on [the proposed solution’s] ability to have a measurable impact on the delivery of care.” While it may be some time before outpatient PCI seems as routine as an ACL repair, that path has begun. Assessing each patient with CTA+HeartFlow will be essential to covering the ground ahead as we shift toward SDD and sites of service which will increase the accessibility and patient-friendliness of PCI.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

1. See Rao, et al. J Am Coll Cardiol 2021. 2. Driessen, et al. J Am Coll Cardiol 2019. Nørgaard, et al. Euro Radiology 2015.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.